Contact: info@alspinc.com
Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
vvvNeurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
44M people world wide
...are living with neurodegenerative disease and the impact is more than doubled when care givers and family members are included.

44M people world wide


-
...TBI increases risk of dementia by as much as two-fold
  
44M people world wide
44M People World Wide

...are living with neurodegenerative disease and the impact is more than doubled when care givers and family members are included...

Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 

 

        News and Events 2012

 


December 4, 2012: Dr. Michael D. Pierschbacher, CEO, ALSP, announced that Dr. Stephen Jacobsen, Ph.D., joined the ALSP Scientific Advisory Board. Dr. Pierschbacher said “We are honored that Steve has joined our team. His international stellar reputation for innovation in Alzheimer’s disease drug development and his in-depth understanding of the pharmaceutical industry will help accelerate our program to the clinic.”


***


October 13 - 17, 2012: Presentation at SOCIETY OF NEUROSCIENCE MEETING in New Orleans LA


>Cathepsin B is an important therapeutic target for traumatic brain injury by Hook G., Yu J., Sipes N., Pierschbacher M., and Kindy M. Read...
>Cathepsin B is an important therapeutic target for traumatic brain injury by Hook G., Yu J., Sipes N., Pierschbacher M., and Kindy M. Read...
>Cathepsin B is an important therapeutic target for traumatic brain injury by Hook G., Yu J., Sipes N., Pierschbacher M., and Kindy M.
>Cathepsin B is an important therapeutic target for traumatic brain injury by Hook G., Yu J., Sipes N., Pierschbacher M., and Kindy M. Read...

***


Presentation on October 13 - 17, 2012, at SOCIETY OF NEUROSCIENCE MEETING in New Orleans LA
>Cathepsin B is an important therapeutic target for traumatic brain injury by Hook G., Yu J., Sipes N., Pierschbacher M., and Kindy M. Read...
***

September 5, 2012: Dr. Michael D. Pierschbacher, CEO, ALSP, announced that Dr. Bernice Wells, MD, MBA,  joined the ALSP Board of Directors.  Dr. Pierschbacher said “Bernice is truly an exceptional individual as she has extensive venture capital experience, pharmaceutical industry experience and is a physician.  Her business and technical insight will help insure ALSP succeeds.”


***


July 16 - 18, 2012: Presentation at American Alzheimer's International Conference (AAIC) in Vancouver, Canada


>Cathepsin B gene deletion or inhibition improves memory deficits in mouse model of Alzheimer's disease expressing APP with the wild-type beta-secretase site by Kindy M., Yu J., Kindy M., Yu J., Zhu H., El-Amouri S, Hook G., and Hook V. 


***


>Deletion of the cathepsin B gene improves memory deficits in an Alzheimer's disease (AD) mouse model expressing APP with the wild-type beta-secretase site, representing most AD patientsby Hook, V., Yu, J, Zhu, H., El-Amouri, S., Hook, G., and Kindy, M.
May 14 - 15, 2012: The National Institute on Aging's Alzheimer's Disease Research Summit, Bethesda, MD

>The National Institute on Aging's Alzheimer's Disease Research Summit was held in Bethesda, MD, at which Health and Human Services Secretary Kathleen Sebelius released the ambitious national plan to fight Alzheimer's disease called the National Alzheimer's Project (NAPA), which set forth five goals, including the development of an effective treatment for Alzheimer's disease by 2025. The meeting called for public comment on how to achieve those goals. Dr. Greg Hook, VP Research, ALSP, and Dr. Vivian Hook, Professor, UCSD and ALSP Scientific Advisor Chair, attended and participated in the meeting as well as provided recommendations to NAPA. 

***

>Deletion of the cathepsin B gene improves memory deficits in an Alzheimer's disease (AD) mouse model expressing APP with the wild-type beta-secretase site, representing most AD patientsby Hook, V., Yu, J, Zhu, H., El-Amouri, S., Hook, G., and Kindy, M.

April 21-25, 2012: Presentation at THE AMERICAN SOCIETY FOR MOLECULAR BIOCHEMISTRY AND MOLECULAR BIOLOGY in San Diego, CA.

>Deletion of the cathepsin B gene improves memory deficits in an Alzheimer's disease (AD) mouse model expressing APP with the wild-type beta-secretase site, representing most AD patientsby Hook, V., Yu, J, Zhu, H., El-Amouri, S., Hook, G., and Kindy, M.

>Deletion of the cathepsin B gene improves memory deficits in an Alzheimer's disease (AD) mouse model expressing APP with the wild-type beta-secretase site, representing most AD patients by Hook, V., Yu, J, Zhu, H., El-Amouri, S., Hook, G., and Kindy, M.


representing most AD patientsby Hook, V., Yu, J, Zhu, H., El-Amouri, S., Hook, G., and Kindy, M.

representing most AD patientsby Hook, V., Yu, J, Zhu, H., El-Amouri, S., Hook, G., and Kindy, M.

representing most AD patientsby Hook, V., Yu, J, Zhu, H., El-Amouri, S., Hook, G., and Kindy, M.


>Deletion of the cathepsin B gene improves memory deficits in an Alzheimer's disease (AD) mouse model expressing APP with the wild-type beta-secretase site, representing most AD patientsby Hook, V., Yu, J, Zhu, H., El-Amouri, S., Hook, G., and Kindy, M.

representing most AD patientsby Hook, V., Yu, J, Zhu, H., El-Amouri, S., Hook, G., and Kindy, M.

***